Resultado clínico del tratamiento endovascular con balón liberador de fármaco en el paciente claudicante con enfermedad femoropoplítea
Open Access
- 10 June 2025
- journal article
- Published by Revista Argentina de Cardiologia in Revista Argentina de Cardiologia
Abstract
Background: Restenosis continues to be the great challenge of endovascular therapy, and drug-eluting balloons (DEB) have been developed to reduce it. The aim of this study was to analyze the results of this therapy. Methods: A retrospective analysis of 40 limbs with femoropopliteal lesions treated with DEB was conducted in patients with intermittent claudication. Results: Technical success was obtained in the 40 (100%) limbs treated, without evidence of serious complications related with treatment, and with 92.5% of asymptomatic limbs during the follow-up period of 11.1 months. In three limbs, a new angioplasty was performed due to symptomatic recurrence. Conclusions: The drug-eluting balloon has proven to be a useful, safe and effective tool for the treatment of de novo and in-stent restenosis lesions; however, TASC C-D lesions require the use of greater number of stents.Keywords
This publication has 3 references indexed in Scilit:
- Paclitaxel-Eluting Balloon vs. Standard Angioplasty to Reduce Recurrent Restenosis in Diabetic Patients With In-Stent Restenosis of the Superficial Femoral and Proximal Popliteal Arteries: The DEBATE-ISR StudyJournal of Endovascular Therapy, 2014
- The LEVANT I (Lutonix Paclitaxel-Coated Balloon for the Prevention of Femoropopliteal Restenosis) Trial for Femoropopliteal RevascularizationJACC: Cardiovascular Interventions, 2014
- Classification and Clinical Impact of Restenosis After Femoropopliteal StentingJACC, 2012